s6y

CDT Equity Inc.

Ticker
CDT, CDTTW
CIK
1896212
Industry
Pharmaceutical Preparations
Formerly
CONDUIT PHARMACEUTICALS INC., Murphy Canyon Acquisition Corp.

Financials 29

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Mar 31, 2026
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2025
  7. 10-Q Quarterly Report for period ending Sep 30, 2025
  8. 10-Q Quarterly Report for period ending Jun 30, 2025
  9. 10-Q/A Quarterly Report for period ending Mar 31, 2025
  10. 10-Q Quarterly Report for period ending Mar 31, 2025

All 29 financials filings

News 82

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 82 news filings

Ownership 90

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4/A Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 90 ownership filings

Prospectus 69

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. S-1 General form of registration statement for all companies including face-amount certificate companies

All 69 prospectus filings

Proxies 18

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 18 proxies filings

Other 87

  1. SCHEDULE 13D/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13D/A
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G/A
  8. EFFECT Notice of Effectiveness
  9. SCHEDULE 13G
  10. SCHEDULE 13G

All 87 other filings